Pfizer's experimental drug to treat sickle cell anemia failed to meet the main goal in a late stage trial, the drugmaker said ...

Pfizer (PFE) stock slips as a Phase 3 trial failure for its sickle cell disease therapy inclacumab marks the latest setback ...

In the latest setback for Pfizer's sickle cell anemia treatments, experimental drug inclacumab failed to meet the main goal ...

Pfizer's inclacumab fails Phase III study for sickle cell disease, disappointing the community while the company remains ...

The FDA’s announcement of Papzimeos’ approval contained an unusual quote from newly reinstated CBER director Vinay Prasad. Elsewhere, Eli Lilly and Superluminal Medicines struck a deal.

The Food and Drug Administration could pull Pfizer's coronavirus vaccine emergency authorization for children under age 5.

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

Several workers reported symptoms of being exposed to a substance and some were taken to the hospital. The state is ...

The potential move to rescind authorization of Pfizer's vaccine could leave some kids in the U.S. with no available shots ...

Pfizer (PFE 0.06%) has been a terrible investment over the past three years. Revenue and earnings have generally moved in the wrong direction, as the company has been unable to fo ...

We recently published 10 Stocks Jim Cramer Discussed As He Questioned Official Data. Pfizer Inc. (NYSE:PFE) is one of the ...

‘It’s not illegal to be homeless’: disquiet as Trump crews clear DC encampments AG showdown: DC attorney general rejects US ...